Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance
Reference number: TA284
Published: 22 May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service
25 March 2013
(314.8 Kb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 March 2013